This is a working overview of Angiotensin IV analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-13. Anything still debated is marked as such rather than presented as settled.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
The next mission, Apollo 10, conducted a "dress rehearsal" for the first landing in May 1969, flying the LM in lunar orbit as close as 47,400 feet (14.4 km) above the surface, the point where the powered descent to the surface would begin. With the LM proven to work well, the next step was to attempt the landing. Unknown to the Americans, the Soviet Moon program was in deep trouble. After two successive launch failures of the N1 rocket in 1969, Soviet plans for a piloted landing suffered delay. The launch pad explosion of the N-1 on July 3, 1969, was a significant setback. The rocket hit the pad after an engine shutdown, destroying itself and the launch facility. Without the N-1 rocket, the USSR could not send a large enough payload to the Moon to land a human and return him safely.
=== Artificial perspiration === Artificial skin capable of sweating similar to natural sweat rates and with the surface texture and wetting properties of regular skin has been developed for research purposes. Artificial perspiration is also available for in-vitro testing, and contains 16 amino acids and the most abundant minerals and metabolites in sweat.
=== Temperature === Conversion of both CO and CO2 to CH4 starts at a catalyst temperature below 300°C, but the conversion is incomplete and peak tailing is evident. At around 340°C, conversion is complete, as indicated by area measurements, but some tailing limits the peak height. At 360-380°C, tailing is eliminated and there is little change in peak height up to 400°C. Operating temperatures for various methanizers range from 350-400°C. Although carbonization of CO has been reported at temperatures above 350°, it is rather a rare phenomenon.
Sources: en.wikipedia.org
=== Awards received in the 2000s === COLACRO (Congreso Latinoamericano de Cromatografia) Merit Medal; Pittsburgh Analytical Chemistry Award; Eastern Analytical Symposium Award for Outstanding Achievements in the Fields of Analytical Chemistry; Tracy M. Sonneborn Award for Outstanding Research and Teaching, Indiana University; Dal Nogare Award in Chromatography; CaSSS (California Separation Science Society) Award for Excellence in Separation Science; Honorary Member of the Slovak Pharmaceutical Society; Foreign Member of the Learned Society of the Czech Republic (Czech Academy of Sciences); American Chemical Society Award in Analytical Chemistry; Jan Weber Prize and Medal, Slovak Pharmaceutical Society, Slovakia; Ralph N. Adams Award in Bioanalytical Chemistry.
== Pathology == Histopathologically, several characteristics are frequently visible in urethral diverticula. These include nephrogenic adenoma, chronic inflammation associated with fibrosis around the glands, small or absent epithelium, chronic cystitis, cystitis cystica, cystitis glandularis, squamous metaplasia, and adenomatous metaplasia. Approximately 1/3 of diverticula are compound or multiple, and some can extend to surround the urethra.
=== Global security program === The Lab's work in global security aims to reduce and mitigate the dangers posed by the spread or use of weapons of mass destruction and by threats to energy and environmental security. Livermore has been working on global security and homeland security for decades, predating both the collapse of the Soviet Union in 1991 and the September 11, 2001, terrorist attacks. LLNL staff have been heavily involved in the cooperative nonproliferation programs with Russia to secure at-risk weapons materials and assist former weapons workers in developing peaceful applications and self-sustaining job opportunities for their expertise and technologies. In the mid-1990s, Lab scientists began devising improved biodetection capabilities, leading to miniaturized and autonomous instruments that can detect biothreat agents in a few minutes instead of the days to weeks previously required for DNA analysis. Livermore researchers address a spectrum of threats – radiological/nuclear, chemical, biological, explosives, and cyber. They combine physical and life sciences, engineering, computations, and analysis to develop technologies that solve real-world problems. Activities are grouped into five programs:
Troika co-founder Jason Anderson's research on Vampire: The Masquerade source material and fansites found that the game's main attraction was character interaction and involvement in the vampire societies, not statistics and powers. Troika tried to remain faithful to the pen-and-paper role-playing game, hoping not to alienate the game's fans, but rules designed for multiple players did not translate well to single-player computer game design. The team attempted to discover which elements could work equally well in pen-and-paper and computer games. However, although much of the character system and attributes were translated, not all the attributes (such as "knowledge of law") made sense in the computer game. Of 30 pen-and-paper abilities, 15 reached the final design. Another difficult area was feats. Although common feats worked well, with a random chance of success or failure, uncommon ones would appear to fail more often. To avoid this, randomization was replaced by a degree of difficulty in accomplishing the feat. Although pen-and-paper falling damage is random, the computer game bases damage on the distance of the fall. The team's biggest challenge was adapting disciplines. The pen-and-paper version may require a little blood that requires a long time to use or have no blood cost and can be used at will; upgraded disciplines had additional requirements considered too confusing for a computer game.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.